论文部分内容阅读
[目的]观察罗格列酮对急性胰腺炎患者肝损伤的保护作用。[方法]选取2013年2月~2016年1月我院收治的急性胰腺炎患者90例,使用数字法随机分为常规治疗对照组和罗格列酮观察组,每组45例。ELISA法检测ALT、AST、TNF-α和IL-1。比较2组临床疗效。[结果]治疗前对照组和观察组ALT、AST、TNF-α和IL-1表达无显著性差异(P>0.05)。治疗5d后2组ALT、AST、TNF-α和IL-1表达均减低(P<0.05和P<0.01),但观察组对ALT、AST、TNF-α和IL-1的减低作用均优于对照组(P<0.05和P<0.01)。对照组腹痛、腹胀缓解时间、排气、通便时间、体温恢复正常时间以及住院时间分别为:5.17±1.09d、4.95±1.02d、4.56±0.82d和15.27±3.81d,均显著高于观察组的3.44±0.76d、3.26±0.75d、3.13±0.64d和9.86±3.06d(P<0.05)。观察组的临床治疗有效率为88.9%(40/45),显著优于对照组的71.1%(32/45)(P<0.05)。[结论]罗格列酮抑制急性胰腺炎患者炎症反应,保护肝功能,临床疗效显著。
[Objective] To observe the protective effect of rosiglitazone on liver injury in patients with acute pancreatitis. [Methods] Ninety cases of acute pancreatitis admitted to our hospital from February 2013 to January 2016 were randomly divided into routine treatment control group and rosiglitazone observation group, with 45 cases in each group. ALT, AST, TNF-α and IL-1 were detected by ELISA. The clinical efficacy of two groups were compared. [Results] The levels of ALT, AST, TNF-α and IL-1 in control group and observation group before treatment were not significantly different (P> 0.05). After 5 days of treatment, the expressions of ALT, AST, TNF-α and IL-1 in the two groups were decreased (P <0.05 and P <0.01), but the reduction effects of ALT, AST, TNF- Control group (P <0.05 and P <0.01). The abdominal pain, abdominal distension time, excretion, laxativeness, body temperature recovery time and hospital stay in the control group were 5.17 ± 1.09d, 4.95 ± 1.02d, 4.56 ± 0.82d and 15.27 ± 3.81d, respectively, which were significantly higher than those of the observation group 3.44 ± 0.76d, 3.26 ± 0.75d, 3.13 ± 0.64d and 9.86 ± 3.06d (P <0.05) for the group. The effective rate of clinical treatment in observation group was 88.9% (40/45), which was significantly better than that in control group (71.1%, 32/45) (P <0.05). [Conclusion] Rosiglitazone can inhibit the inflammatory response in patients with acute pancreatitis and protect the liver function.